Paycor HCM's new guidance indicates sustainable mid-teens recurring revenue growth. Click here to read why I've upgraded PYCR ...

NervGen's groundbreaking NVG-291 treatment for spinal cord injury is currently in trials with FDA Fast Track Designation.

The current fears surrounding Google seem, in my opinion, overly inflated. Click here to read why GOOG stock remains a Buy.

We caution investors on Vistra, highlighting overvaluation despite growth and green initiatives. See why we suggest a hold on ...

Mastercard is a solid long-term investment with strong growth prospects, driven by its global reach and innovative business ...

T. Rowe Price Ultra Short-Term Bond ETF has a 5.3% yield with low volatility and alternative options for minimal ...

Over the course of the last two years, equity investors in the S&P 500 stocks have enjoyed a cumulative price only return of 57.3% ...

NNN REIT's dividend of 5.7% is well-supported by current earnings. Click here to read why growth potential is limited for NNN stock.

We recommend holding Adobe stock, with a potential buy opportunity at $350, citing strong cash flow and AI potential. Read an ...

Ares Capital's mix of floating rate debt principal outstanding has been steadily increasing since Q1 FY22. Read why ARCC ...

TSMC's dominance in advanced semiconductor manufacturing positions it as a key player in the AI revolution. Read what makes ...

Gold's recent surge is driven by Chinese demand and concerns about monetary stability. Click here to read why my outlook on ...